一、论文 1. Zhao H, Yang T, Yue L, Li H, Xie T, Xiang H, Wang J, Wei X, Zhang Y, Xie Z. Comparative analysis of the biological characteristics of three CV-A10 clones adaptively cultured on Vero cells. J Med Virol. 2022,94(8):3820-3828. 2. Yuan J, Zhang Q, Chen S, Yan M, Yue L*. LC3-Associated Phagocytosis in Bacterial Infection. Pathogens. 2022,11(8):863. 3. Xie T, Lu S, He Z, Liu H, Wang J, Tang C, Yang T, Yu W, Li H, Yang Y, Yang H, Yue L, Zhou Y, Yang F, Luo Z, Li Y, Xiang H, Zhao Y, Wang J, Wang H, Long R, Kuang D, Tan W, Peng X, Li Q, Xie Z. Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern. Signal Transduct Target Ther. 2022,7(1):61. 4. Yue L, Xie T, Yang T, Zhou J, Chen H, Zhu H, Li H, Xiang H, Wang J, Yang H, Zhao H, Wei X, Zhang Y, Xie Z. A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine. J Med Virol. 2022,94(1):35-38. 5. Yue L, Zhou J, Zhou Y, Yang X, Xie T, Yang M, Zhao H, Zhao Y, Yang T, Li H, Xiang H, Wang J, Lu S, Liu H, Zhao H, Wei X, Zhang Y, Xie Z. Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern. Emerg Microbes Infect. 2021, 10(1):2125-2127. 6. Yue L, Cao H, Xie T, Long R, Li H, Yang T, Yan M, Xie Z. N‐terminally truncated nucleocapsid protein of SARS‐CoV‐2 as a better serological marker than whole nucleocapsid protein in evaluating the immunogenicity of inactivated SARS‐CoV‐2. Journal of Medical Virology. 2021,93(3):1732-1738. 二、专利 1. 一株可适用于人用疫苗细胞基质培养的柯萨奇病毒A组10型疫苗株及其应用,授权 2. 一种适用于柯萨奇病毒A6培养的新型稳转细胞系及其应用,授权 三、科技成果 无 |
用户登录
还没有账号?
立即注册